Kenneth Hoberman
Directeur des opérations chez STEMLINE THERAPEUTICS, INC.
Fortune : 4 M $ au 30/04/2024
Postes actifs de Kenneth Hoberman
Sociétés | Poste | Début | Fin |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Directeur des opérations | 01/01/2013 | - |
Secrétaire Général | 01/01/2013 | - | |
TG THERAPEUTICS, INC. | Directeur/Membre du Conseil | 15/12/2014 | - |
Independent Dir/Board Member | 15/12/2014 | - | |
NUVECTIS PHARMA, INC. | Directeur/Membre du Conseil | 01/07/2021 | - |
Independent Dir/Board Member | 01/07/2021 | - | |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Directeur/Membre du Conseil | 01/11/2021 | - |
Historique de carrière de Kenneth Hoberman
Anciens postes connus de Kenneth Hoberman
Sociétés | Poste | Début | Fin |
---|---|---|---|
KERYX BIOPHARMACEUTICALS | Corporate Officer/Principal | 01/01/2004 | 01/01/2012 |
Formation de Kenneth Hoberman
Boston University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Israël | 2 |
Opérationnelle
Director/Board Member | 3 |
Independent Dir/Board Member | 2 |
Chief Operating Officer | 1 |
Sectorielle
Health Technology | 6 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
TG THERAPEUTICS, INC. | Health Technology |
NUVECTIS PHARMA, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- Kenneth Hoberman
- Expérience